What trends show in MDT's past year earnings?

Medtronic's (MDT) past year earnings show a mixed performance with both positive and negative trends:

1. **Overall Growth**: Medtronic has demonstrated a positive outlook with year-to-date returns of 14.56% and a 15.2% return over the past year. This indicates a general upward trend in the company's stock performance.
2. **Quarterly Performance**: The company's financial performance in the second quarter of FY25 presented a mixed picture with a slight fall in quarterly revenue missing consensus expectations but earnings per share (EPS) exceeding analyst projections. In Q3 FY25, Medtronic reported a 2.5% increase in revenue and a 7% increase in non-GAAP diluted EPS.
3. **Segmental Performance**: Specific segments like Diabetes showed strong growth with an 8.4% increase, while Neuromodulation also performed well driven by Pain Stim growth. However, the Surgical Innovations division faced a shortfall due to distributor de-stocking, impacting overall revenue.
4. **Market Position**: Despite the challenges, Medtronic maintained a positive outlook for FY25, anticipating year-over-year organic sales growth of 4.75-5.0% and EPS growth of 10-11% excluding foreign exchange impacts. The company's strategic initiatives and innovative products are expected to drive future growth.

In conclusion, Medtronic has shown resilience with positive returns and growth in certain segments, although it has faced some challenges such as distributor purchasing shifts and revenue shortfalls in specific divisions. The company's overall outlook remains optimistic, supported by its innovation pipeline and strategic direction.